LBLuca Borradori

Luca Borradori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luca Borradori has a total of 495 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Th2/Th17 Inflammation: Pathogenic Drivers and Therapeutic Targets in Darier and Hailey‐Hailey Diseases

    by Ella Glodjajic, Darko Stojkov, Joanna Boros‐Majewska, Jeremy Di Domizio, Michel Gilliet, Christoph Schlapbach, Timothée Fettrelet, Luca Borradori, Hans‐Uwe Simon, Dagmar Simon, et al.

    Background: The inherited acantholytic dermatoses Darier disease (DD) and Hailey‐Hailey disease (HHD) are characterized by a barrier dysfunction of the epidermis susceptible to inflammation and microbial infections. Objectives: This study aimed at investigating the expression of inflammatory and epithelial barrier markers in DD and HHD in order to identify potential targets for novel treatment strategies. Methods: In this retrospective study, 6 DD and 4 HHD patients were included, of which three (1 DD, 2 HHD) have received targeted anti‐inflammatory therapies. To visualize inflammatory and barrier markers, immunofluorescence techniques were applied on skin biopsies. Gene expression patterns were analyzed in skin specimens of DD and HHD patients (each n = 2). Results: A mixed interleukin (IL)‐13/IL‐17 expression was observed in both DD and HHD. The numbers of IL‐13+ cells were significantly higher in HHD compared with DD ( p = 0.0143; 2.27, CI 95% (0.73, 3.74)). The analysis of gene expression patterns revealed a mixed Th17/Th2/eosinophil signature in lesional skin of DD, and a Th17 signature in HHD. Thymic stromal lymphopoietin was noticed in DD and HHD skin, while an aberrant, weak or missing expression of E‐cadherin, filaggrin and cathelicidin was observed. Treatment with dupilumab or secukinumab was effective in all three patients; however, the latter had to be stopped because of skin infections. Limitations: Limitations of the study are the retrospective design, lack of genetic results, low numbers of patients and tissue samples, as well as the preliminary results on the efficacy of biologics in DD and HHD. Conclusions: DD and HHD are characterized by Th2 and Th17 immune responses that might result in further epidermal barrier disruption. Thus, reducing the inflammation seems a worth treatment approach, even though the efficacy and safety of targeted therapies have to be proven in larger patient cohorts.

  • Open Access

    The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data

    by Luigi Naldi, Simone Cazzaniga, Carsten Flohr, Marco May Lee, Claire Fuller, Roderick Hay, Esther E. Freeman, Rashmi Sarkar, Ricardo Romiti, Antonio Torrelo, et al.

    Background: Skin diseases represent a major public health concern, affecting all demographics and imposing significant personal, economic and social burdens. Objectives: To assess the epidemiology and impact of skin diseases using the Global Burden of Disease (GBD) data, highlighting regional variations, knowledge gaps and areas for improvement. Methods: GBD data on prevalence, incidence, disability‐adjusted life years (DALYs) and years lived with disability (YLDs) for skin conditions from 2000 to 2021 were analysed. Results: According to GBD 2021, the global prevalence of skin and subcutaneous diseases, excluding sexually transmitted infections (STIs) and skin cancers, was 25.7%, ranking sixth among the most prevalent disease categories worldwide. These conditions accounted for a global YLDs rate of 495.1 per 100,000 person‐years, placing them eighth in terms of disease burden. Overall, the most prevalent conditions were STIs excluding HIV (16.8%), fungal infections (7.8%), and acne (3.0%). Squamous cell carcinoma, basal cell carcinoma and decubitus ulcers showed increasing prevalence, while atopic dermatitis, scabies and viral infections declined slightly. Acne, scabies and atopic dermatitis predominated in youth, whereas fungal infections, contact dermatitis and skin cancers predominated in older adults. Females showed higher prevalence of STIs, acne and atopic dermatitis. Infectious skin diseases were more common in Sub‐Saharan Africa and tropical regions, while chronic inflammatory and neoplastic diseases predominated in high‐income regions. Conclusions: Several limitations were identified. The GBD initiative only includes some dermatological diseases reflecting the difficulties in obtaining data because of the multitude of skin diseases with underreporting and misdiagnosis. There are significant gaps in data from low‐ and middle‐income countries, a lack of reliable trends and inadequate quality‐adjusted life year estimates considering cultural and social variations. The GBD initiative provides valuable insights but underestimates the true burden of skin diseases. Improved reporting and inclusion of neglected conditions are urgently needed through global collaboration among stakeholders.


  • International development of Investigator Global Assessment scores for pemphigus

    by Dédée F. Murrell, Darby Boucher, Maryam Daneshpazhooh, Hamidreza Mahmoudi, Nika Kianfar, Shayan Dasdar, Marc Yale, Anna Wilson, Asli Bilgic, Soner Uzun, et al.

  • Open Access

    Efficient On‐Column Removal of Endotoxin from Immunoglobulins Such as AK23

    by Siavash Rahimi, Patrizia Sauta, Monika Edler, Elisabeth Locher, Marlies Illi, Taravat Shojaeian, Luca Borradori, Thomas Gentinetta, William V. J. Hariton, Eliane J. Müller

    Unattended endotoxin (ETX) contamination in biological samples constitute a major challenge for in vitro and in vivo applications. Besides being potentially life‐threatening, ETX contamination is especially relevant in global transcriptome analyses, where competing ETX stimulation can significantly skew the final gene expression profile. Our studies in mice and cultured skin epithelial cells (epidermal keratinocytes) aiming to characterize the effect of antibodies such as AK23 immunoglobulins (IgG directed against the cell‐cell adhesion molecule desmoglein [DSG] 3) in the autoimmune disease pemphigus vulgaris (PV) revealed that laboratory‐produced and even commercial control antibodies can exhibit non‐negligible ETX contaminations. Moreover, these contaminants are extremely difficult to remove. To overcome these challenges, we have devised a simple yet nontoxic and scalable two‐step protocol to efficiently reduce ETX levels during or after the IgG purification process. It consists firstly of 0.5 M NaOH pre‐treatment of all devices, including the protein A resin, used during IgG sanitization and purification, in parallel with meticulous in‐process monitoring of ETX levels. Secondly, before IgG elution from protein A, ETX is stripped from IgG by ion‐exchange with the common amino acid arginine. This two‐step approach successfully reduces ETX by >95% from hybridoma‐derived, laboratory‐produced AK23 IgG, as well as patient PV and control IgG, resulting in an 85% IgG recovery rate and ETX levels compatible with U.S. Pharmacopeia guidelines. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Sanitization of devices and protein A resin with 0.5 M NaOH Basic Protocol 2 : On‐column stripping of ETX from AK23 IgG Basic Protocol 3 : Quality control of sanitized AK23 IgG

  • Open Access

    Standardized indirect immunofluorescence-based detection of dermal-binding autoantibodies in pemphigoid diseases: a prospective international multicentre study

    by Sabrina Patzelt, Rengin Melis Engin, Kossara Drenovska, Charlotte Kiehne, Christian Probst, Lars Komorowski, Swantje Mindorf, Maryam Daneshpazhooh, Soo-Chan Kim, Francesca Farnetani, et al.

    We evaluated a Biochip™-based immunofluorescence assay for improved diagnosis of dermal-binding pemphigoid diseases by detecting autoantibodies against laminin β4, type VII collagen and laminin 332. Results showed high sensitivity, with anti-p200 pemphigoid (laminin β4 reactivity) being more frequent than epidermolysis bullosa acquisita, suggesting underdiagnosis in clinical practice. The Biochip mosaic is a valuable tool for the parallel detection of key autoantibodies, potentially enhancing diagnostic accuracy and patient management.


  • Open Access

    Bilateral Nicolau Syndrome Following Intramuscular Gentamicin Injections

    by Konstantina Kotsia, Louise Gueissaz, Roland Blum, Luca Borradori

  • Open Access

    Stasis dermatitis and pigmented purpuric dermatoses: Histological characterization and review of literature

    by M. S. Hoffet, D. L. Perruchoud, K. Gadaldi, K. Heidemeyer, S. Bossart, L. Borradori, A. A. Ramelet, L. Feldmeyer

    Background: Stasis dermatitis and pigmented purpuric dermatoses can both manifest as hyperpigmentation, petechiae and/or purpura on the lower extremities, posing a challenge for macroscopic differentiation. We investigated the histological differences in these two conditions.Objectives: To determine the histological characteristics of stasis dermatitis and pigmented purpuric dermatosis.Methods: Skin biopsy specimens were obtained from seven patients with stasis dermatitis, 15 with pigmented purpuric dermatosis, and three control patients. The samples were analysed for histological changes (hematoxylin‐eosin), melanin (silver nitrate), iron, elastic stain, and with an immunohistochemistry for melanocytes (Melan‐A).Results: The predominant histological features of stasis dermatitis were hemosiderin deposits, eosinophils and telangiectasias. Pigmented purpuric dermatosis was characterized by extensive erythrocyte extravasation, interface changes and spongiosis.Conclusions: The distinct histological characteristics of stasis dermatitis and pigmented purpuric dermatosis can improve the diagnostic classification of these entities.


  • Open Access

    Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, Greece

    by Meropi Karakioulaki, Patrick Dunn, Dedee F. Murrell, Aimee Payne, Enno Schmidt, Victoria Werth, Marc Yale, Jun Yamagami, Valeria Aoki, Luca Borradori, et al.


  • Open Access

    Mechanobullous form of epidermolysis bullosa acquisita: Insights into disease mechanisms as inferred by response to rituximab, but not to JAK inhibitors

    by L. Gueissaz, A. Junge, R. Wolf, C. Schlapbach, L. Feldmeyer, L. Borradori

    Epidermolysis bullosa acquisita (EBA) is a rare autoimmune blistering disease associated with IgG autoantibodies directed against type VII collagen. Different clinical forms have been described, including the classical mechanobullous variant resembling epidermolysis bullosa dystrophica, which is typically treatment‐resistant. We here describe a 67‐year‐old patient with a mechanobullous EBA characterized by trauma‐induced blisters on her hands and feet for 9 months. Despite treatments with oral prednisolone, topical steroids or calcineurin inhibitors, doxycycline, ciclosporin, and baracitinib, no improvement was observed. The patient went into complete remission only after administration of rituximab with no lesions off therapy at the 10‐month follow up. Our observation suggests that inflammatory cytokines are not primarily responsible for skin blistering and fragility in mechanobullous EBA. The effectiveness of rituximab provides some insights into the major direct role of autoantibodies in mediating dermo‐epidermal separation in this variant of EBA.

  • Open Access

    Dermatological emergencies and determinants of hospitalization in Switzerland: A retrospective study

    by S. Cazzaniga, K. Heidemeyer, C. A. Zahn, S. M. Seyed Jafari, T. C. Sauter, L. Naldi, L. Borradori

    Background: Dermatologic conditions are estimated to account worldwide for approximately 8% of all visits at emergency departments (EDs). Although rarely life‐threatening, several dermatologic emergencies may have a high morbidity. Little is known about ED consultations of patients with dermatological emergencies and their subsequent hospital disposal.Objective: We explore determinants and clinical variables affecting patients' disposal and hospitalization of people attending the ED at a Swiss University Hospital, over a 56‐month observational period, for a dermatological problem.Methods: De‐identified patients' information was extracted from the hospital electronic medical record system. Generalized estimating equations were used to explore determinants of patient's disposition.Results: Out of 5096 consecutive patients with a dermatological main problem evaluated at the ED, 79% of patients were hospitalized after initial assessment. In multivariable analyses, factors which were significantly associated with an increased admission rate included length of ED stay, age ≥ 45 years, male sex, distinct vital signs, high body mass index, low oxygen saturation, admission time in the ED and number and type of dermatological diagnoses. Only 2.2% of the hospitalized patients were admitted to a dermatology ward, despite the fact that they had dermatological diagnoses critically determining the diagnostic related group (DRG) payment. The number of patients managed by dermatologists during in‐patient treatment significantly decreased over the study period.Conclusions: Our study identifies a number of independent predictors affecting the risk of hospital admission for patients with dermatological conditions, which may be useful to improve patients' disposal in EDs. The results indicate that the dermatological specialty is becoming increasingly marginalized in the management of patients in the Swiss hospital setting. This trend may have significant implications for the delivery of adequate medical care, outcomes and cost‐effectiveness. Dermatologists should be more engaged to better position their specialty and to effectively collaborate with nondermatologists to enhance patient care.